FDA Investigator Jennifer A Kemp
Jennifer A Kemp has conducted inspections on 72 sites in 1 countries as of 06 Nov 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
72
Last Inspection Date:
06 Nov 2023
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Jennifer A Kemp:
Alanna L Mussawwir Bias,
Albert F Peacock, PhD,
Amy S Graf,
Andrace L Deyampert,
Andrea D Swingle,
Angela J Alexander,
Anthony R Petriella,
Anya Dlockett Evans,
Art O Czabaniuk,
Ashley E Lewis,
Azza Talaat,
Barbara A Rusin,
Bei Y He,
Benjamin J Smith,
Bleta Vuniqi,
Byron Ho, DVM,
Byungja E Marciante,
Carmen M Faraianu,
Caroline H Le,
Catherine V Quinlan,
Cathie S Marshall,
Charles I Ann,
Charles L Zhou,
Chelsea W Lamm,
Cheryl A Fuhs,
Cheryl M Monroe,
Constantin Y Philopoulos,
Corrine M Carter,
Crystal L Parks,
Crystal M Young Lewis,
Cynthia L Aycock,
Cynthia Li,
Daniel B Bordt,
Darla J Christopher,
Darren S Morgan,
David A Paterson,
David P Moorhead,
David Perkins,
Deanna L Lampley,
Debara R Reese,
Debara Reese,
Denise L Burosh,
Dennis E Guilfoyle, PhD,
Dina A Tallman,
Donald C Obenhuber, PhD,
Emest F Bizjak,
Emily B Camire,
Emily J Orban,
Erma Zaimova,
Gabryelle J Solverud,
Geneve M Maxwell,
Jacob A Clark,
Jean Blackston Hill,
Jeffrey A Sommers,
Jeffrey D Meng,
John N Woodall,
Joseph A Piechocki,
Joseph R Strelnik,
Judith A Jankowski,
Karen M Montgomery (KMM),
Kathryn A Cutajar,
Kathryn A Guardiola,
Kathryn G Brown,
Kelley L Clark,
L'oreal F Walker,
Larry K Austin,
Laureen F Kononen,
Lauren E Burke,
Lauren Iacono Connors, PhD,
LCDR Anastasia M Piliafas Brown,
Leigh Anne Myers,
Lesley Maep Lutao,
Leslie A Paul,
Lillie M Young,
Linda S Jozefiak,
Lisa J Joseph,
Lisa M Bellows,
Lisa P Oakes,
LT Danielle S Mills,
LTJG Aaron B Otis,
Luella J Rossi,
Margaret N Persich,
Marlon K Turner,
Martha Sullivan Myrick,
Martin R Vowell,
Matthew J Gretkierewicz,
Meisha R Sampson,
Meisha Waters,
Melina Lrodriguez Upton,
Melisa A Healy,
Mercy Oyugi,
Michael Shanks, MS,
Michael Y Philopoulos,
Michele L Forster, PhD,
Michelle L Jones,
Mikhail V Ovanesov, PhD,
Montgomery Montgomery, Karen M,
Muna Algharibeh,
Myra K Casey,
Nailing Zhang,
Nancy A Bellamy,
Neali H Lucas,
Patricia A Cochran,
Patricia H Dlugosz,
Patricia M Jacobs,
Patrick B Cummings,
Patsy J Domingo,
Qiao Y Bobo,
Rabin N Ghoshal,
Rafeeq A Habeeb,
Rasha Bamieh,
Raymond T Oji,
Rebecca E Dombrowski,
Regina T Brown,
Reginald Walker,
Renee L Rice, PhD,
Robert D Tollefsen,
Robert J Ham,
Robert M Barbosa,
Robert P Whisenant,
Roger A Hartman,
Rohn R Robertson,
Ronda Rloyd Jones,
Sandra A Boyd,
Sandra A Hughes,
Sanket N Patel,
Sarah M Meng,
Sarah M Napier,
Sherri J Jackson,
Susan F Laska, MS,
Susan M North,
Susan P Bruederle,
Suyang Qin,
Thomas J Arista,
Thuy T Nguyen, LCDR,
Tina M Pawlowski,
Tracey Asinjen Wiersma,
Tracey L Siebesma,
Travis S Bradley,
Twana R Chandler,
Wayne E Seifert,
William D Tingley,
Yangmin Ning,
Yumi J Hiramine
Jennifer A Kemp's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| October, 2022 | FDA 483 | Jeffrey W. Taub, M.D. - Form 483, 2022-10-12 |
| June, 2023 | FDA 483 | Dennis Hammond - Form 483, 2023-06-20 |
| May, 2023 | FDA 483 Response | Cem Akin, M.D. - Form 483R, 2023-05-31 |
| July, 2021 | EIR | LabCorp Indiana Inc. - EIR, 2021-07-13 |
| February, 2022 | FDA 483 | Octapharma Plasma Inc - Form 483, 2022-02-14 |
| September, 2023 | FDA 483 | Eli Lilly and Company - Form 483, 2023-09-15 |
| August, 2023 | FDA 483 | Miguelangelo J. Perez-Cruet, M.D., M.S. - Form 483, 2023-08-25 |
| May, 2023 | FDA 483 | Cem Akin, M.D. - Form 483, 2023-05-10 |
| April, 2023 | FDA 483 | Dipenkumar Modi, M.D. - Form 483, 2023-04-12 |
| March, 2022 | FDA 483 | CSL Plasma Inc. - Form 483, 2022-03-10 |
| September, 2022 | FDA 483 | University Of Michigan - IRBMED - Form 483, 2022-09-02 |
| July, 2021 | FDA 483 | LabCorp Indiana Inc. - Form 483, 2021-07-13 |
| August, 2021 | FDA 483 | Biograft Transplant Services Inc - Form 483, 2021-08-27 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more